Clinical and economic impact of recurrence in unresected non–small cell lung cancer treated with primary stereotactic body radiotherapy: A real-world study using SEER-Medicare data
Recurrence after SBRT in unresected, early-stage NSCLC was associated with worse survival and substantial economic burden. The strong correlation between rwEFS and OS suggests that EFS may serve as a good predictor for OS and be a clinically relevant trial endpoint. These findings highlight the need for novel strategies to prevent/delay recurrence.
Authors
- Anya Jiang
- Su Zhang (ORCID: https://orcid.org/0000-0002-5928-6360)
- Yan Song (ORCID: https://orcid.org/0000-0003-2215-1101)
- James Signorovitch (ORCID: https://orcid.org/0000-0002-4067-8962)
- Ashwini Arunachalam (ORCID: https://orcid.org/0000-0003-4879-4770)
- Megan E. Daly (ORCID: https://orcid.org/0000-0001-7308-6149)
- Ayman Samkari
- Andrew Song (ORCID: https://orcid.org/0000-0001-8386-4397)
- Jiayang Li (ORCID: https://orcid.org/0000-0001-9271-3988)
- Pei Jiang (ORCID: https://orcid.org/0000-0003-2947-3701)
- Pragya Rai (ORCID: https://orcid.org/0000-0003-0856-9050)
- Chi Gao (ORCID: https://orcid.org/0000-0003-1873-2296)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- UC Davis Comprehensive Cancer Center
- Analysis Group (United States) (US)
- University of California, Davis (US)
Publication Details
- Journal
- Journal of Managed Care & Specialty Pharmacy
- Published
- 2025-09-26
- DOI
- https://doi.org/10.18553/jmcp.2025.31.10.1006
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00